Summary
KalVista is riding upon a successful phase 1 trial for DME, where KVD001 was well tolerated and signal of improved visual acuity followed after one single dose.
Expect top-line results for its phase 2 clinical trial of KVD001 in 123 DME patients to be released in the second half of 2019.
Merck is quite bullish on KalVista as shown through its partnership and also acquiring a 9.9% ownership stake in the company.
Merck holds the option to acquire KVD001 upon completion of the Phase 2 proof-of-concept trial.
Background
KalVista Pharmaceuticals (KALV) is a clinical-stage pharmaceutical company focused on the development of small molecule protease inhibitors. The company is still in its infancy and market cap is a mere $121 million. KalVista focuses on two franchises: hereditary angioedema (HAE) and diabetic macular edema (DME). This article will discuss solely about DME.
